Co-diagnostics, inc. reports full year 2023 financial results

Salt lake city , march 14, 2024 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended december 31, 2023. full year  2023 financial results: revenue of $6.8 million, down from $34.2 million during the prior year primarily due to the decline in global demand for the logix smart® covid-19 tests.
CODX Ratings Summary
CODX Quant Ranking